Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolazamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolazamide SCHEMBL747962 | 0.96 | ALDH1A1 (0.65) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Tolazamide SCHEMBL992662 | 0.88 | ALDH1A1 (0.75) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Glypinamide SCHEMBL5243890 | 0.85 | ALDH1A1 (0.59) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Tolazamide SCHEMBL13725632 | 0.84 | ALDH1A1 (1.00) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Tolazamide SCHEMBL34417 | 0.84 | ALDH1A1 (1.00) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Glypinamide SCHEMBL343885 | 0.84 | ALDH1A1 (0.74) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Tolbutamide SCHEMBL12498646 | 0.83 | ALDH1A1 (0.82) | ALDH1A1CYP3A4NFKB1MAPTLMNA | |
| Tolazamide SCHEMBL28562527 | 0.83 | ALDH1A1 (0.97) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Glyclopyramide SCHEMBL15669226 | 0.82 | ALDH1A1 (0.71) | ALDH1A1CYP3A4NFKB1MAPTKDM4E | |
| Glyclopyramide SCHEMBL49354 | 0.82 | ALDH1A1 (0.71) | ALDH1A1CYP3A4NFKB1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256146-A1 | DERMATOPONTIN AS A THERAPEUTIC FOR METABOLIC DISORDERS | Agency for Science, Technology and Research (A*STAR) (SG) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016130085-A1 | DERMATOPONTIN AS A THERAPEUTIC FOR METABOLIC DISORDERS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-18 | — | — | WO | disclosed |
| US-20110257239-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND METHOD OF RELEASING PHARMACEUTICALLY ACTIVE AGENT | SHAH RAJEN | 2011-10-20 | — | — | US | disclosed |
| US-20100311802-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND METHOD OF RELEASING PHARMACEUTICALLY ACTIVE AGENT | SHAH RAJEN | 2010-12-09 | — | — | US | disclosed |
| EP-1121116-B1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION OF FLUVASTATIN | NOVARTIS AG (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-20060159754-A1 | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent | SHAH RAJEN | 2006-07-20 | — | — | US | disclosed |
| US-20020169145-A1 | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent | SHAH RAJEN (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1121116-A2 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND METHOD OF RELEASING PHARMACEUTICALLY ACTIVE AGENT | Novartis AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021525-A2 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND METHOD OF RELEASING PHARMACEUTICALLY ACTIVE AGENT | NOVARTIS AG (CH) | 2000-04-20 | — | — | WO | disclosed |
| US-5929055-A | Therapeutic method for management of diabetes mellitus | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-07-27 | — | — | US | disclosed |